Spondyloarthritis, Axial
9
4
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis
Influence of Air Pollution on SPondyloarthritis Flare-ups and Resistance to Treatment
Influence of Sodium Intake in spondyLoarthriTes
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Biologic Treatment Registry Across Canada
Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy
Severity Over Time of Early Forms of Spondyloarthritis
Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib
Cohort Project of Patients With Inflammatory Rheumatism